Bempedoic Acid TBM BE study in SBOA [BE/BA News]

posted by dshah  – India/United Kingdom, 2022-03-30 19:09 (435 d 21:50 ago) – Posting: # 22889
Views: 1,125

(edited by dshah on 2022-03-31 11:42)

Hello All!

I was going through SBOA of Bempedoic acid marketed as Nexleton tablets.
In general, a BE study of Phase III vs TBM formulation can suffice the need for clinical significance. But in what condition, FDA can waive such condition of BE of TBM formulation with Phase III formulations in IND filing? [image]
or considering the biopharmaceutics risk assessment- it is a low risk and study can be waived?
[image]
Regards,
Divyen Shah

Complete thread:

UA Flag
Activity
 Admin contact
22,627 posts in 4,743 threads, 1,613 registered users;
23 visitors (0 registered, 23 guests [including 14 identified bots]).
Forum time: 16:59 CEST (Europe/Vienna)

Facts are meaningless. You could use facts to prove
anything that’s even remotely true!    Homer Simpson

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5